Related Experiment Video
Updated: May 24, 2026

Closure of a Patent Foramen Ovale (PFO): An Intervention Sequence
Published on: December 23, 2022
Reduction in postoperative high-density lipoprotein cholesterol levels in children undergoing the Fontan operation
Sinai C Zyblewski1, W Scott Argraves, Eric M Graham
1Department of Pediatrics, Division of Pediatric Cardiology, Medical University of South Carolina, 165 Ashley Ave, MSC 915, Charleston, SC 29425, USA. chois@musc.edu
Insights
High-density lipoprotein-cholesterol (HDL-C) levels significantly decrease in children after the Fontan operation. Lower HDL-C may be linked to longer chest tube drainage and chylous effusions post-cardiac surgery.
Area of Science:
- Pediatric Cardiology
- Cardiovascular Surgery
- Lipid Metabolism
Background:
- High-density lipoprotein (HDL) plays a role in vascular integrity and inflammation.
- HDL levels in pediatric cardiac surgery patients remain largely unstudied.
- The Fontan operation is a complex procedure for single-ventricle patients.
Purpose of the Study:
- To investigate high-density lipoprotein-cholesterol (HDL-C) levels in children before and after the Fontan operation.
- To explore the relationship between postoperative HDL-C levels and the duration and type of pleural effusions.
Main Methods:
- Prospective enrollment of 12 pediatric patients undergoing the Fontan operation.
- Measurement of plasma HDL-C levels pre- and post-cardiopulmonary bypass.
- Analysis of chest tube drainage duration and effusion type (chylous vs. nonchylous).
- Statistical analysis using Kendall rank correlation and Wilcoxon rank sum test.
Main Results:
- A significant reduction in median HDL-C levels was observed post-cardiopulmonary bypass (30 mg/dl pre- vs. 21 mg/dl post-, p=0.004).
- A trend towards an inverse correlation between post-bypass HDL-C and chest tube drainage duration was noted (r=-0.42, p=0.07).
- Post-bypass HDL-C levels tended to be lower in patients with chylous effusions (16 mg/dl vs. 23 mg/dl, p=0.09).
Conclusions:
- The Fontan operation leads to a significant decrease in plasma HDL-C levels in pediatric patients.
- Reduced HDL-C may be associated with increased risk or severity of postoperative pleural effusions.
- Further research is warranted to understand HDL's role in post-cardiac surgery recovery and effusion management.
Abstract:
Despite the emerging relevance of high-density lipoprotein (HDL) in the inflammatory cascade and vascular barrier integrity, HDL levels in children undergoing cardiac surgery are unexplored. As a measure of HDL levels, the HDL-cholesterol (HDL-C) in single-ventricle patients was quantified before and after the Fontan operation, and it was determined whether relationships existed between the duration and the type of postoperative pleural effusions. The study prospectively enrolled 12 children undergoing the Fontan operation. Plasma HDL-C levels were measured before and after cardiopulmonary bypass. The outcome variables of interest were the duration and type of chest tube drainage (chylous vs. nonchylous). The Kendall rank correlation coefficient and the Wilcoxon rank sum test were used. There were 11 complete observations. The median preoperative HDL-C level for all the subjects was 30 mg/dl (range, 24-53 mg/dl), and the median postcardiopulmonary bypass level was 21 mg/dl (range, 14-46 mg/dl) (p = 0.004). There was a tendency toward a moderate inverse correlation (-0.42) between the postcardiopulmonary bypass HDL-C level and the duration of chest tube drainage, but the result was not statistically significant (p = 0.07). In the chylous effusion group, the median postcardiopulmonary bypass HDL-C tended to be lower (16 vs. 23 mg/dl; p = 0.09). After the Fontan operation, the plasma HDL-C levels in children are significantly reduced. It is reasonable to conclude that the reduction in HDL-C reflects reduced plasma levels of HDL particles, which may have pertinent implications in postoperative pleural effusions given the antiinflammatory and endothelial barrier functions of HDL.
Related Concept Videos
Atherosclerosis III: Management
Coronary Artery Disease IV: Preventive Measures
Lipid-Lowering Drugs: Statins and Miscellaneous Agents